• Explore /
  • Poster
  • / Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.

Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.

Abstract Poster

Authors

null

Xuewen Ma

Janssen Research & Development, Spring House, PA

Xuewen Ma , Jue Gong , Jie Zhou , Dongfen Yuan , Deeksha Vishwamitra , Brandi Hilder , Tara J. Masterson , Jaszianne A. Tolbert , Thomas Renaud , Christoph Heuck , Colleen Kane , Mahesh N. Samtani , Suzette Girgis , Jesus G. Berdeja , Amrita Y. Krishnan , Daniele Ouellet

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03399799/NCT04634552

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8041)

DOI

10.1200/JCO.2023.41.16_suppl.8041

Abstract #

8041

Poster Bd #

33

Abstract Disclosures

Similar Posters

First Author: Kristoffer Staal Rohrberg

First Author: Shaji Kumar

First Author: Paul G. Richardson

First Author: Krish Patel